Болезнь Альцгеймера
https://doi.org/10.14412/2074-2711-2019-3S-52-60
Аннотация
Несмотря на прогресс в сфере лабораторных методов, генетических исследований и современной нейровизуализации, диагностика заболеваний, обусловливающих деменцию, вызывает сложности. В обзоре представлены современные данные, касающиеся эпидемиологии, факторов риска, патогенеза, клинической картины, диагностики и терапии болезни Альцгеймера (БА). Обсуждаются вопросы симптоматических и патогенетических методов лечения, а также комбинированной терапии БА. Отмечаются эффективность мемантина (акатинола мемантина) и целесообразность его использования на разных стадиях заболевания у пациентов с БА. Рассматриваются немедикаментозные методы терапии БА, включая физическую активность и когнитивный тренинг.
Об авторе
Н. Н. Коберская
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет) Минздрава России
Россия
Россия
кафедра нервных болезней и нейрохирургии лечебного факультета,
119021, Москва, ул. Россолимо, 11, стр. 1
Список литературы
1. Prince M, Wimo A, Guerchet M, et al. An analysis of prevalence, incidence, cost & trends. In: Alzheimer's Disease International. World Alzheimer Report 2015. The global impact of dementia. London; 2015.
2. Парфенов ВА, Кабаева АР. Ведение пациентов с болезнью Альцгеймера. Медсовет. 2018;(1):6-11.
3. Белоусов ЮБ, Зырянов СК, Белоусов ДЮ, Бекетов АС. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. 2009;(1):3-28.
4. Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014.
5. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. New Engl J Med. 2013;368(14):1326-34. doi: 10.1056/NEJMsa1204629
6. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi: 10.2147/CLEP.S37929
7. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785-96. doi: 10.1016/S1474-4422 (11)70156-9
8. Liesinger AM, Graff-Radford NR, Duara R, et al. Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathol. 2018;136:873-85. doi: 10.1007/s00401-018-1908-x
9. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM incidence research group and work groups. European studies of Dementia. Neurology. 1999;52:78-84. doi: 10.1212/WNL.52.1.78
10. Chene G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham heart study from mid-adult life. Alzheimer's Dement. 2015;11:310-20. doi: 10.1016/j.jalz.2013.10.005
11. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385: 2255-63. doi: 10.1016/S0140-6736(15)60461-5
12. Gauthier S, Zhang H, Ng KP, et al. Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology. Translat Neurodegenerat. 2018;7:12. doi: 10.1186/s40035-018-0117-9
13. Xu W, Tan L, Wang HF, et al. Education and Risk of Dementia: Dose-Response MetaAnalysis of Prospective Cohort Studies. Mol Neurobiol. 2016 Jul;53(5):3113-23. doi: 10.1007/s12035-015-9211-5. Epub 2015 May 17.
14. Meng X, D'Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. PLoS One. 2012;7:38268. doi: 10.1371/journal.pone.0038268
15. Mehta KM, Stewart AL, Langa KM, et al. «Below average» self-assessed school performance and Alzheimer's disease in the Aging, Demographics, and Memory Study. Alzheimers Dement. 2009;5:380-7. doi: 10.1016/j.jalz.2009.07.039
16. Snowdon DA, Greiner LH, Markesbery WR. Linguistic ability in early life, the neuropathology of Alzheimer's disease, cerebrovascular disease Findings from the Nun Study. Ann N Y Acad Sci. 2000;903:34-8. doi: 10.1111/j.1749-6632.2000.tb06347.x
17. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life, cognitive function Alzheimer's disease in late life Findings from the Nun Study. JAMA. 1996; 275:528-32. doi: 10.1001/jama.1996.03530310034029
18. De Luca V, Orfei MD, Gaudenzi S, et al. Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7): 599-606. doi: 10.1007/s00406-015-0663-4. Epub 2015 Dec 29.
19. Dean DC 3rd, Jerskey BA, Chen K, et al. Brain Differences in Infants at Differential Genetic Risk for Late-Onset Alzheimer Disease: A Cross-sectional Imaging Study. JAMA Neurol. 2014;71(1):11-22. doi: 10.1001/jamaneurol.2013.4544
20. Shaw P, Lerch JP, Pruessner JC, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007;6:494-500. doi: 10.1016/S1474-4422(07)70106-0
21. Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis. 2010;22: 307-13. doi: 10.3233/JAD-2010-100129
22. Bloss CS, Delis DC, Salmon DP, Bondi MW. Decreased cognition in children with risk factors for Alzheimer's disease. Biol Psychiatry. 2008;64:904-6. doi: 10.1016/j.biopsych.2008.07.004
23. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and lateonset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3:569-74. doi: 10.1093/hmg/3.4.569
24. Nicolas G, Charbonnier C, Wallon D, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular Psychiatry. 2016;21(6):831-6. doi: 10.1038/mp.2015.121
25. Bralten J, Arias-Vasquez A, Makkinje R, et al. Association of the Alzheimer's gene SORL1 with hippocampal volume in young, healthy adults. Am J Psychiatry. 2011;168: 1083-9. doi: 10.1176/appi.ajp.2011.10101509
26. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12: 957-65. doi: 10.1016/S1474-4422(13)70194-7
27. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17-24. doi: 10.1002/ana.410410106
28. Chertkow H, Feldman HH, Jcova C, et al. Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013;5(Suppl 1).
29. Яхно НН, Коберская НН, Захаров ВВ и др. Влияние возраста, коморбидных сердечно-сосудистых и эмоциональных факторов на легкое когнитивное снижение в среднем, пожилом и старческом возрасте. Неврологический журнал. 2018;23(6):309-15.
30. Dubois B, Hampel H, Feldman HH, et al. Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on «The Preclinical State of AD»; July 23, 2015; Washington DC, USA. Alzheimers Dement. 2016;12:292-323. doi: 10.1016/j.jalz.2016.02.002
31. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014; 84:608-22. doi: 10.1016/j.neuron.2014.10.038
32. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386-95. doi: 10.1016/j.jalz.2011.05.2243
33. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 2007;6:734-46. doi: 10.1016/S1474-4422(07)70178-3
34. Mapstone M, Cheema AK, Fiandaca MS, et al. (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20:415-8. doi: 10.1038/nm.3466
35. Yerbury JJ, Poon S, Meehan S, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007;21: 2312-22. doi: 10.1096/fj.06-7986com
36. Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305:1322-6. doi: 10.1001/jama.2011.381
37. Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-16. doi: 10.1016/S1474-4422(12)70291-0
38. Ossenkoppele R, Schonhaut DR, Schö ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139:1551-67. doi: 10.1093/brain/aww027
39. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379-85. doi: 10.1001/jamaneurol.2014.2031
40. Onyike CU, Chaney G-AS. Alzheimer Disease at the Extremes of Age: Clinical Epidemiology, Diagnosis and Care. Alzheimer's Association International Conference, AAIC. London; 2017.
41. Giacobini E. Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: Giacobini E, Pepeu G, editors. The Brain Cholinergic System in Health and Disease. Oxon, UK: Informa Healthcare; 2006. P. 235-64.
42. Pharmaceutical Research and Manufacturers of America. Researching Alzheimer's Medicines: Setbacks and Stepping Stones. 2012.
43. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383-8. doi: 10.1016/0165-6147(91)90609-V
44. Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci. 2017;24:47. doi: 10.1186/s12929-017-0355-7
45. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-Amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012;32:9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012
46. Doody RS, Thomas RG, Farlow M, et al. (2014) Phase 3 trials of solanezumab for mildto-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21. doi: 10.1056/NEJMoa1312889
47. Sevigny J, Chiao P, Bussiere T, et al. (2016) The antibody aducanumab reduces A plaques in Alzheimer's disease. Nature. 2016;537:50-6. doi: 10.1038/nature19323
48. Liang J, Li J, Jia R. Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review. Clin Intervent Aging. 2018;13:2061-73. doi: 10.2147/CIA.S184968
49. Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer's disease: The path to 2025. Alzheimer's Res Ther. 2016 Sep 20;8(1):39. doi: 10.1186/s13195-016-0207-9
50. Schmidt R, Ropele S, Ebenbauer B, et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurol. 2007;14(1):2526.
51. Inoue Y, Ueda M, Masuda T, et al. Memantine attenuates vascular amyloid β deposits and spontaneous hemorrhages in mouse models of cerebral amyloid angiopathy. Alzheimer's Association International Conference, AAIC. London; 2017.
52. Walker V, Davies N, Kehoe P, et al. What isthe impact of regulatory guidance and expiry ofdrug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. Alzheimers Res Ther. 2018 May 29;10(1):51. doi: 10.1186/s13195-018-0379-6
53. Erickson KI, Raji CA, Lopez OL, et al. Physical activity predicts gray matter volume in late adulthood: The Cardiovascular Health Study. Neurology. 2010;75:1415-22. doi: 10.1212/WNL.0b013e3181f88359
54. Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment: A 6-month randomized controlled trial. Arch Intern Med. 2013;172:666-8. doi: 10.1001/archinternmed.2012.379
55. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521-34. doi: 10.1002/ana.22089
56. Leinenga G, Gö tz J. Scanning ultrasound removes amyloid- and restores memory in an Alzheimer's disease mouse model. Sci Transl Med. 2015;7:278ra33. doi: 10.1126/scitranslmed.aaa2512
57. Коберская НН. Современные представления о факторах риска, диагностике и терапии болезни Альцгеймера (по материалам Международной конференции Ассоциации болезни Альцгеймера, Лондон, 2017). Неврология, нейропсихиатрия, психосоматика. 2017;9(3):81-7. doi: 10.14412/2074-2711-2017-3-81-87
58. Коберская НН. Ранняя диагностика болезни Альцгеймера. Эффективная фармакотерапия. Неврология. 2017;3(31):20-7.
Рецензия
Для цитирования:
Коберская НН. Болезнь Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):52-60. https://doi.org/10.14412/2074-2711-2019-3S-52-60
For citation:
Koberskaya NN. Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):52-60. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3S-52-60
Просмотров:
1382
Послать статью по эл. почте 